EGFR and lip and oral cavity carcinoma: Multiple studies have shown the use of Epidermal Growth Factor Receptor (EGFR)-targeted fluorescent tracers (e.g., panitumumab-800CW and cetuximab-800CW) to detect malignant LNs ex vivo in oral cancer patients using fluorescence molecular imaging [35], [36].